Amgen Inc. (AMGN)

In the past six months, Amgen's stock has experienced several notable events. As of May 5, 2026, the share price was $329.59, representing an increase of 21.87% over the past year. On May 1, 2026, Amgen's shares fell 5% despite reporting revenue and earnings growth, partly attributed to analyst downgrades, elevated net debt, and insider selling. Competition has intensified for key Amgen drugs, with sales declines in Prolia, Xgeva, and Enbrel. Amgen also faced clinical setbacks, halting trials for several drugs due to failed efficacy tests or safety concerns. Despite these challenges, Amgen's Q1 2026 results showed growth in key areas, and the company announced an additional investment in its Puerto Rico manufacturing facility.

While specific seasonality for individual products is not extensively documented, there is a general acknowledgment of demand seasonality within the pharmaceutical and biotechnology industry. Amgen's Q1 2026 earnings report indicated that revenue trends are consistent with normal seasonal sequencing. Amgen employs strategies like maintaining manufacturing plants and investing in inventory management to mitigate risks from unexpected increased product demand and ensure a reliable supply.

Amgen Inc. is a multinational biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. The company operates within the biotechnology sector, focusing on prescription medicines for areas including general medicine, rare diseases, inflammation, and oncology/hematology, encompassing cardiovascular and bone diseases. Amgen's major products include Prolia, XGEVA, Enbrel, Repatha, Otezla, Tepezza, Evenity, Kyprolis, Nplate, Aranesp, Blincyto, Aimovig, Neulasta, Tezspire, Vectibix, and Lumakras. The company also has a growing biosimilars business.

Amgen has a global presence, reaching patients in approximately 100 countries. The United States is Amgen's largest market, accounting for 72.8% of its sales in 2024. The company has manufacturing facilities, including a site in Puerto Rico, and a distribution center in Breda, the Netherlands. Amgen also established its European headquarters in Lucerne, Switzerland, later relocating to Zug, and has a presence in Ireland with commercial teams in Santry and manufacturing facilities in Dún Laoghaire and Waterford.

Amgen has maintained a strong brand reputation, receiving accolades such as being named one of the "World's Most Ethical Companies®" by Ethisphere and included in Forbes' list of "America's Best Large Employers." Amgen was also recognized as a top pharma company by patient organizations. However, Amgen's reputation faced a challenge due to a dispute with the FDA regarding its drug, Tavneos, with concerns about data manipulation and potential withdrawal from the market.

Amgen's ownership is predominantly held by institutional investors, who typically hold between 76.50% and 82.06% of the company's stock. As of May 7, 2026, Amgen Inc. has 3135 institutional owners and shareholders holding a total of 437,023,058 shares. The Vanguard Group Inc. is the largest individual Amgen shareholder, owning 54.84 million shares, representing 10.17% of the company. Individual insiders and employees hold a considerably smaller percentage of shares, ranging from 0.19% to 1.01%.